These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14989386)

  • 1. Unanswered questions on omalizumab (Xolair) patient selection and follow-up.
    Lanier B; Marshall GD
    Ann Allergy Asthma Immunol; 2004 Feb; 92(2):198-200. PubMed ID: 14989386
    [No Abstract]   [Full Text] [Related]  

  • 2. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for asthma.
    Strunk RC; Bloomberg GR
    N Engl J Med; 2006 Jun; 354(25):2689-95. PubMed ID: 16790701
    [No Abstract]   [Full Text] [Related]  

  • 5. Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
    Liebhaber M; Dyer Z
    J Asthma; 2007 Apr; 44(3):195-6. PubMed ID: 17454337
    [No Abstract]   [Full Text] [Related]  

  • 6. After 6 years with Xolair; a 3-year withdrawal follow-up.
    Nopp A; Johansson SG; Adédoyin J; Ankerst J; Palmqvist M; Oman H
    Allergy; 2010 Jan; 65(1):56-60. PubMed ID: 19796193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intubation secondary to asthma exacerbation in a patient with asthma receiving Xolair (omalizumab).
    Jacobs ZD; Guajardo JR
    Pediatr Pulmonol; 2008 Jan; 43(1):102-3. PubMed ID: 18041749
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab for asthma.
    Winchester DE; Jacob A; Murphy T
    N Engl J Med; 2006 Sep; 355(12):1281-2. PubMed ID: 16990394
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment.
    Ruppert AM; Averous G; Stanciu D; Deroide N; Riehm S; Poindron V; Pauli G; Debry C; de Blay F
    J Allergy Clin Immunol; 2008 Jan; 121(1):253-4. PubMed ID: 18206510
    [No Abstract]   [Full Text] [Related]  

  • 12. The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.
    Sthoeger ZM; Eliraz A; Asher I; Berkman N; Elbirt D
    Isr Med Assoc J; 2007 Jun; 9(6):472-5. PubMed ID: 17642399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in children: a negative risk-benefit balance in severe persistent asthma.
    Prescrire Int; 2011 Apr; 20(115):92. PubMed ID: 21648208
    [No Abstract]   [Full Text] [Related]  

  • 16. [Omalizumab (Xolair). Product description].
    Laursen LC
    Ugeskr Laeger; 2007 Mar; 169(11):993-5. PubMed ID: 17371630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab for asthma.
    Tonnel AB; Tillie-Leblond I
    N Engl J Med; 2006 Sep; 355(12):1282. PubMed ID: 16998966
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma.
    Korn S; Schumann C; Kropf C; Stoiber K; Thielen A; Taube C; Buhl R
    Ann Allergy Asthma Immunol; 2010 Oct; 105(4):313-9. PubMed ID: 20934632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Omalizumab. A monoclonal antibody against IgE].
    Hennemann A
    Med Monatsschr Pharm; 2004 Dec; 27(12):404-7. PubMed ID: 15646688
    [No Abstract]   [Full Text] [Related]  

  • 20. Allergy, Allergic Inflammation and Asthma--Keystone Symposium. Pharmacological targets in allergic inflammation and asthma.
    Kierstein S
    IDrugs; 2006 Jun; 9(6):405-8. PubMed ID: 16752308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.